Effects of Amlodipine in the Management of Chronic Heart Failure

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients with congestive heart failure are usually treated with a combination of an ACE inhibitor (or an AT1 blocking agent), a diuretic and a beta-blocker. However, some patients remain symptomatic despite an optimal treatment with these drugs. In patients who also have coronary heart disease, nitrates or some calcium-channel blockers could help to relieve symptoms. Therefore, the aim of our study is to evaluate the additional benefit induced by a second generation calcium-channel blocker, amlodipine, in patients with chronic heart failure who remain symptomatic despite an optimal treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rennes University Hospital
• Treatments: Amlodipine

Criteria

Inclusion Criteria:

• Patients over 18 years

• Chronic heart failure with New York Heart Association class III or IV.

• Ischemic or dilated cardiopathy known for at least 3 months

• Systolic arterial pressure > 110 mmHg under treatment

• Stroke volume between 20 and 40% under treatment

• Informed written consent

Exclusion Criteria:

• History of allergy to one of the studied pharmaceutical classes

• History of troubles in ventricular rythm (tachycardia, fibrillation) or acute heart failure

• Chronic renal, hepatic or respiratory failure

• Diabetes

• Valvulopathy

• Myocarditis,constrictive pericarditis

• Life prognosis < 6 months due to a non cardiac pathology

• Absence of woman contraception, pregnancy, breast-feeding

• Treatment with calcium channel blockers or antiarrythmics class IC

• Unstable patient under standardized treatment

• Unable to do a stress test